Theratechnologies Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic solutions for patients with unmet medical needs, particularly in the areas of endocrine and metabolic disorders
The company is primarily engaged in creating treatments that target specific conditions related to aging and severe hormonal imbalances, leveraging its expertise in peptide and protein therapeutics. Through its research and development efforts, Theratechnologies aims to improve the quality of life for patients while advancing scientific understanding in its therapeutic areas.
U.S. stock futures were trading lower on Wednesday, after advancing for three consecutive sessions. Futures of major benchmark indices were lower in premarket trading.
Theratechnologies anticipates a temporary supply disruption of Egrifta SV in 2025 due to an FDA-linked manufacturer shutdown, but the company is working to minimize the impact while adjusting revenue projections for 2024.
Theratechnologies reports Q2 2024 sales of $22.02 million, a 25.5% YoY increase, driven by strong demand for EGRIFTA SV. Net income reached $1 million with an adjusted EBITDA of $5.5 million. The company expects FY 2024 revenue of $87-$90 million and adjusted EBITDA of $13-$15 million.
Companies Reporting Before The Bell • Delta Air Lines (NYSE:DAL) is projected to report quarterly earnings at $0.35 per share on revenue of $12.55 billion.
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.
Gainers Appreciate Holdings, Inc. (NASDAQ: SFR) shares surged 103.8% to $0.2460 in pre-market trading after falling around 19% on Wednesday. Appreciate Holdings received a notice from Nasdaq regarding delisting.
Gainers Biocept, Inc. (NASDAQ: BIOC) shares jumped 97.6% to $1.6608 after the company announced non-exclusive licensing agreement for CNSide with Plus Therapeutics.
